Mass General has teamed up with the Broad Institute of MIT and Harvard and Amgen to develop and test new therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. Through this collaboration, scientists with expertise in areas ranging from clinical medicine to human genetics will partner together to create therapeutic options for patients with IBD. We are thrilled to be working together with our Amgen colleagues in this visionary collaboration, said Dr. Ramnik Xavier, chief of gastroenterology and director of the Center for the Study of Inflammatory Bowel Disease at Mass General.
Posted on: Fri, 17 Jan 2014 19:55:15 +0000